Clinical trials: Coronary Artery Disease Progression
Coronary Artery Disease
Prediction of Atherosclerotic Plaque Progression
To predict coronary atherosclerosis progression in patients with acute coronary syndrome by the use of intracoronary imaging methods.
- Trial name
- PPP (NCT05424705)
- Testing
- OCT, NIRS
- Where
- Czechia
- Volunteers
- 40 people
- Sponsor
- Na Homolce Hospital
Metabolic Syndrome
Carnitine for the Treatment of Atherosclerosis.
Obesity is one of the main causes of the metabolic syndrome, a condition which is becoming more common in Canada and worldwide. Metabolic syndrome is a name for a group of heart disease risk factors that occur together: obesity…
- Trial name
- ECoM (NCT02117661)
- Testing
- L-carnitine capsules, Cellulose capsules
- Where
- 2 sites in Canada
- Volunteers
- 177 people
- Sponsor
- Dr. Amer Johri
Coronary Disease, Young Adult
Risk Prediction of Disease Progression in Early-Onset Coronary Atherosclerosis
This study is part of a nationwide research project in China that aims to better understand how coronary artery disease develops and progresses in young adults.
- Trial name
- NCT07316452
- Where
- China
- Volunteers
- 10,000 people
- Sponsor
- Fu Wai Hospital, Beijing, China
Atherosclerosis, Cardiovascular Diseases
Epidemiology of Carotid IMT Progression in MESA - Ancillary Study
To determine the factors associated with progression of sub-clinical atherosclerosis and to evaluate the associations between the progression of sub-clinical atherosclerosis and the development of clinically manifest…
- Conditions
- Atherosclerosis, Cardiovascular Diseases, Heart Diseases, Carotid Artery Diseases
- Trial name
- NCT00063440
- Volunteers
- 5,610 people
- Sponsor
- Tufts Medical Center
Diabetes Mellitus
Efficacy Study of Pioglitazone Compared to Glimepiride on Coronary Atherosclerotic Disease Progression in Subjects With Type 2 Diabetes Mellitus
The purpose of this study was to determine the efficacy of pioglitazone, once daily (QD), compared to glimepiride on atherosclerotic disease measured by intravascular ultrasound.
- Trial name
- PERISCOPE (NCT00225277)
- Testing
- Pioglitazone, Glimepiride
- Where
- 79 sites in United States, Argentina and 2 more
- Volunteers
- 547 people
- Sponsor
- Takeda
Acute Coronary Syndrome, Atherosclerosis
Synergy Between morpHOlogical and inflammatoRy Evaluation in Predicting Long-term Coronary Plaque Progression
Data from human autopsy studies have showed that thrombosis of a ruptured plaque with a large necrotic core, inflammatory cells and a thin fibrous cap, the so-called thin cap fibroatheroma (TCFA), represents the main mechanism…
- Conditions
- Acute Coronary Syndrome, Atherosclerosis, Inflammation, Coronary Artery Disease
- Trial name
- SHORE (NCT05436977)
- Testing
- coronary OCT, 68GaDOTATATE PET/CTCA
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- University of Bologna
Diabetes Mellitus, Acute Coronary Syndrome
The POST-ACS Study
Individuals with T2DM have a two-fold excess risk of cardiovascular (CV) events compared with their non-diabetic counterparts. Although it is the primary cause of death in T2DM, there is no significant evidence that intensive…
- Conditions
- Diabetes Mellitus, Acute Coronary Syndrome, Coronary Artery Disease
- Trial name
- NCT05322200
- Testing
- A computerized tomography (CT) coronary angiogram, Vicorder (Skidmore medical, UK), Blood tests for inflammation and oxidative stress markers
- Where
- United Kingdom
- Volunteers
- 140 people
- Sponsor
- Swansea Bay University Health Board
Coronary Artery Occlusive Disease
A Trial Comparing the Effect of Pravastatin and Rosuvastatin on Atherosclerosis Progression Measured by Carotid Intima Media Thickness in Patients With Coronary Artery Disease After Biolimus Eluting Stent (Nobori®) Implantation: CPR IMT
Current consensus papers recommend statin medication to reduce Low density lipoprotein (LDL) cholesterol level less than 100mg/dL (optional 70mg/dL) in patients with coronary artery disease.
- Trial name
- NCT01872845
- Testing
- Pravastatin 40mg, Rosuvastatin
- Where
- South Korea
- Volunteers
- 671 people
- Sponsor
- Yonsei University
Cardiovascular Diseases, Cardiovascular Abnormalities
Effect of SNF472 on Progression of Cardiovascular Calcification in End-Stage-Renal-Disease (ESRD) Patients on Hemodialysis (HD)
The primary objective is to assess the effect of 2 dose levels of SNF472 (300 mg and 600 mg) compared to placebo on the progression of coronary artery calcium volume score over a 12-month (52 weeks) period in ESRD patients on HD
- Conditions
- Cardiovascular Diseases, Cardiovascular Abnormalities, Calcifications, Vascular, Endstage Renal Disease
- Trial name
- NCT02966028
- Testing
- SNF472
- Where
- 75 sites in United States, Spain and 1 more
- Volunteers
- 274 people
- Sponsor
- Sanifit Therapeutics S. A.
Coronary Artery Disease
Effect of Colchicine on Progression of Known Coronary Atherosclerosis in Patients With Stable Coronary Artery Disease
This is a randomized double-blind, placebo-controlled, investigator-initiated trial that compares Colchicine 0.5mg/day with placebo, among patients with stable CAD.
- Trial name
- EKSTROM (NCT06342609)
- Testing
- Colchicine 0.5 MG
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Coronary Artery Disease, Coronary Artery Disease Progression
Critical Treatment of Coronary Artery Disease
Identifying the critical lesion of coronary artery disease and determining the interventional plan are significant for reducing adverse cardiovascular adverse events.
- Trial name
- CTCAD (NCT03195621)
- Testing
- Stent implantation
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Southeast University, China
Heart Failure, Cardiomyopathies
Multimodal Physiologic State Intelligence Study
The OMNIPHYS study will investigate whether multimodal ultrasound and other routinely collected clinical and physiologic data can be combined with artificial intelligence to characterize changes in a person's physiologic state…
- Conditions
- Heart Failure, Cardiomyopathies, Pulmonary Hypertension, Myocarditis; Acute or Subacute
- Trial name
- OMNIPHYS (NCT07814118)
- Testing
- OMNIPHYS Multimodal Ultrasound Imaging System
- Where
- United States
- Volunteers
- 25,000 people, healthy volunteers welcome
- Sponsor
- Truway Health, Inc.
Atherosclerosis
Rivaroxaban Versus Warfarin in the Evaluation of Progression of Coronary Calcium
Current oral anti-coagulation for atrial fibrillation is most commonly performed with warfarin. Warfarin is a vitamin K antagonist that has been shown in non-randomized trials to increase vascular calcification.
- Trial name
- NCT02376010
- Testing
- rivaroxaban, Warfarin
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Coronary Artery Disease
Randomized Controlled Trial of Moderate-Intensity Rosuvastatin With Ezetimibe Combination Therapy Versus High-Intensity Rosuvastatin on Progression of Coronary Atherosclerotic Plaque
The aim of this prospective, open-label, randomized, single center study is to compare the effect of usual dose rosuvastatin plus ezetimibe and high-dose rosuvastatin on modifying atherosclerotic plaque.
- Trial name
- Rosuzet-IVUS (NCT03169985)
- Testing
- Rosuvastatin 10 mg plus ezetimibe 10 mg orally once a day, Rosuvastatin 20 mg orally once a day
- Where
- South Korea
- Volunteers
- 280 people
- Sponsor
- Samsung Medical Center
Coronary Artery Disease
Effect of Statins on the Radial Intima-media Thickness After Transradial Angioplasty
The first event of the atherosclerotic plaque formation is the accumulation of the low density lipoprotein-cholesterol (LDL-cholesterol) in to the intima of the arterial wall.
- Trial name
- NCT00952770
- Testing
- transradial coronary intervention
- Where
- South Korea
- Volunteers
- 140 people
- Sponsor
- Chungnam National University
Coronary Atherosclerosis
STRADIVARIUS (Strategy To Reduce Atherosclerosis Development InVolving Administration of Rimonabant - the Intravascular Ultrasound Study)
The purpose of this study is to determine if rimonabant 20 mg once daily (od) administered during 18-20 months will reduce progression of coronary atherosclerosis as assessed by intravascular ultrasound (IVUS) when administered…
- Trial name
- NCT00124332
- Testing
- Rimonabant (SR141716)
- Where
- 9 sites in United States, Australia and 7 more
- Volunteers
- 839 people
- Sponsor
- Sanofi
Cardiovascular Disease
A Study of the Effect of Dalcetrapib on Artherosclerotic Disease in Patients With Coronary Artery Disease
This multicenter, double-blind, randomized, placebo-controlled study will evaluate the effect of dalcetrapib 600 mg on artherosclerotic disease progression, lipid profile and biomarker profile and long-term safety profile of…
- Trial name
- NCT01059682
- Testing
- Dalcetrapib
- Where
- 110 sites in United States, Canada and 3 more
- Volunteers
- 936 people
- Sponsor
- Hoffmann-La Roche
Melanoma, Atherosclerosis
Statins and prOgression of Coronary atheRosclerosis in melanomA Patients Treated With chEckpoint inhibitorS
This study is a prospective observational study evaluating the natural history of coronary plaque burden in participants with melanoma treated with ICI. The study will be conducted at various sites across Australia.
- Trial name
- SOCRATES (NCT05180942)
- Where
- 12 sites in Australia
- Volunteers
- 130 people
- Sponsor
- Monash University
Coronary Arteriosclerosis, Endothelial Dysfunction
Effect of Aged Garlic Extract (AGE) on Improving Coronary Atherosclerosis in People With Type 2 Diabetes Mellitus
The purpose of this research study is to see the effect of taking Aged Garlic Extract (AGE) on the progression of coronary plaque, a condition called atherosclerosis, in people diagnosed with Diabetes.
- Conditions
- Coronary Arteriosclerosis, Endothelial Dysfunction, Type 2 Diabetes Mellitus
- Trial name
- NCT03931434
- Testing
- Aged Garlic Extract (AGE)
- Where
- United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Coronary Artery Disease (CAD)
Study on Risk Factors and Prognostic Value of Non-target Lesion Progression in Patients With Coronary Artery Disease
The goal of this observational study is to explore the risk factors and prognostic value of non-target coronary lesion progression in patients aged 18-80 years with established coronary artery disease who are scheduled for repeat…
- Trial name
- NCT07748754
- Testing
- Progression of non-target vessels
- Where
- China
- Volunteers
- 1,400 people
- Sponsor
- Beijing Anzhen Hospital